Cerity Partners LLC Has $210.15 Million Holdings in AbbVie Inc. $ABBV

Cerity Partners LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 15.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,132,136 shares of the company’s stock after acquiring an additional 153,108 shares during the quarter. Cerity Partners LLC owned about 0.06% of AbbVie worth $210,152,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Headlands Technologies LLC acquired a new position in shares of AbbVie during the first quarter valued at about $553,000. Donoghue Forlines LLC lifted its stake in shares of AbbVie by 93.8% in the first quarter. Donoghue Forlines LLC now owns 17,484 shares of the company’s stock valued at $3,663,000 after buying an additional 8,462 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of AbbVie by 553.8% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 86,277 shares of the company’s stock valued at $18,077,000 after buying an additional 73,081 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $226.24 on Friday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The business’s fifty day moving average price is $228.30 and its two-hundred day moving average price is $208.35. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock has a market capitalization of $399.85 billion, a price-to-earnings ratio of 171.39, a price-to-earnings-growth ratio of 1.22 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the business earned $3.00 earnings per share. The business’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 496.97%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ABBV shares. Evercore ISI boosted their price target on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Raymond James Financial set a $256.00 target price on AbbVie in a research report on Monday, November 3rd. HSBC set a $225.00 price target on shares of AbbVie in a report on Thursday, October 2nd. Finally, DZ Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.